<DOC>
	<DOCNO>NCT02168101</DOCNO>
	<brief_summary>The purpose study determine whether MLN9708 effective maintenance therapy follow allogeneic stem cell transplant patient high-risk multiple myeloma .</brief_summary>
	<brief_title>Determining Feasibility MLN9708 Maintenance After Allogeneic Stem Cell Transplant Multiple Myeloma</brief_title>
	<detailed_description>Although multiple myeloma consider fatal , survival dramatically improve last two decade introduction effective treatment option . Proteasome inhibitor anti-myeloma effect often use either initial treatment relapse patient multiple myeloma . MLN9708 orally bioavailable , potent , reversible inhibitor 20S proteasome . Phase I study show MLN9708 well tolerate minimal peripheral neuropathy . It also show impressive anti-myeloma activity relapsed/refractory set upfront setting ( Kumar et al . 2011 , Berdeja et al . 2011 , Richardson et al . 2011 ) . These characteristic make MLN9708 ideal proteasome inhibitor use allogeneic stem cell transplant . In Phase II , open-label , multicenter , non-randomized study investigator investigate role MLN9708 maintenance allogeneic stem cell transplant patient high-risk multiple myeloma , patient multiple myeloma relapse autologous stem cell transplant .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>KEY POINTS : 1 . Symptomatic multiple myeloma asymptomatic myeloma myelomarelated organ damage diagnose accord standard criterion patient receive allogeneic transplant due highrisk prognostic feature , , limit : Chromosome 17p , partial deletion [ del ( 17p ) ] , ( 4 ; 14 ) , ( 14 ; 16 ) , ( 14 ; 20 ) Plasma cell leukemia PFS le 2 year autologous stem cell transplant 2 . Evidence engraftment neutrophil ( absolute neutrophil count [ ANC ] &gt; 1000 cells/mm3 ) platelet ( platelet &gt; 60,000 cells/mm3 ) [ dose escalation phase ] &gt; 50,000 cells/mm3 [ dose expansion phase ] ) . 3 . Achievement least PR prior allogeneic stem cell transplant 4 . Adequate liver kidney function 5 . Ability swallow oral medication 6 . Absence gastrointestinal symptom precludes oral intake absorption MLN9708 7 . Off antibiotic amphotericin B formulation , voriconazole antifungal therapy treatment proven , probable possible infection 8 . ECOG ≤ 2 9 . Life expectancy ≥3 month 10 . Ability understand nature study give write informed consent 1 . Patients progressive disease compare pretransplant staging define IMWG Uniform Response criterion Multiple Myeloma . 2 . Umbilical cord blood transplant 3 . Patients &gt; Grade 2 peripheral neuropathy pain , ≥ Grade 3 peripheral neuropathy per NCI CTCAE Version 4.0 4 . Patients uncontrolled bacterial , viral , fungal infection 5 . New York Heart Association ( NYHA ) Class III IV heart failure uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . 6 . Patients pregnant breastfeed 7 . Most recent chemotherapy ≤21 day ≤ Grade 1 chemotherapyrelated side effect , exception alopecia 8 . Use study drug ≤21 day 5 halflives ( whichever short ) prior first dose MLN9708 . For study drug 5 halflives ≤21 day , minimum 10 day termination study drug administration MLN9708 require . 9 . Wide field radiotherapy ( include therapeutic radioisotope strontium 89 ) administer ≤14 day limit field radiation palliation ≤7 day prior start study drug recover side effect therapy 10 . Major surgical procedure ≤14 day begin study drug , minor surgical procedure ≤7 day . No wait require follow portacath placement . 11 . Ongoing active systemic infection . Known diagnosis human immunodeficiency virus , hepatitis B , hepatitis C 12 . Central Nervous System involvement 13 . Known allergy study medication , analogue , excipients various formulation agent . 14 . Systemic treatment moderate strong inhibitor cytochrome P450 ( CYP ) 1A2 , CYP3A , clinically significant CYP3A inducer , use Ginkgo biloba St. John 's wort within 14 day study drug administration study . 15 . Presence active cancer , history treatment invasive cancer ≤5 year . Patients Stage I cancer receive definitive local treatment consider unlikely recur eligible . All patient previously treat situ carcinoma ( i.e. , noninvasive ) eligible , patient history nonmelanoma skin cancer . 16 . Graft versus host disease &gt; Grade 2 ; GVHD grade 1 Grade 2 require &gt; 0.5 mg/kg methylprednisolone , equivalent . There additional Inclusion/Exclusion criterion . The Study Center determine meet criterion answer question may trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MLN9708</keyword>
	<keyword>allogeneic stem cell transplant</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>ixazomib</keyword>
	<keyword>autologous stem cell transplant</keyword>
</DOC>